( ) saw a notable increase in short interest during June. On June 30, there were 2,170,000 short shares, an increase of 6.9% over the total of 2,030,000 on June 15. The short-interest rate is currently 2.1 days based on an average daily share volume of 1,040,000.
The Price of Immunic Performance
The stock fell $0.11 at midday on Thursday to $2.54. The stock was traded at a volume of 904,384 compared to the average of 1,23998. The 50-day moving price of the company is $1.97, and its 200-day moving price is also $1.84. Immunic's twelve-month low is $1.11, and its twelve-month high is $11.76. The last time the company released its results was on Thursday 11th May. The company's ($0.58) earnings per share for the third quarter fell short of analysts' expectations ($0.54), by just ($0.04). Analysts at equities firms expect Immunic to post -2.11 EPS for the current fiscal period.
Wall Street analysts weigh in
Immunic was covered in a report published on Thursday 18th May. The stock was given a "sell" rating. Three investment analysts have given the stock a buy recommendation, while one analyst gave it a sell. According to MarketBeat data, the company's consensus rating is 'Hold' with a consensus target price of $17.75.
Hedge Funds weigh in on Immunic
Recently, several institutional investors increased or decreased their stakes. RTW Investments LP grew its Immunic position by 11.2% during the first quarter. RTW Investments LP owns 4,294,459 of the company stock, valued at $6.399,000. It acquired an additional 433,169 during the period. Gratus capital LLC increased its holdings in Immunic by 121.5% over the fourth quarter. Gratus capital LLC owns now 1,668,294 of the company stock valued at $2,336,000, after buying an additional 915 104 shares. BlackRock Inc. grew its position in Immunic during the first quarter by 0.9%. BlackRock Inc. owns now 1,314,484 of the company’s stock valued at $14,853,000. This is after buying an additional 11,708 share during the period. Artal Group S.A. increased the position it held in Immunic during the fourth quarter by 82.1%. Artal Group S.A. owns 1,274,713 of the company stock valued at $1,785,000, after buying an additional 574 713 shares during the period. Vanguard Group Inc. increased their position in Immunic during the third quarter by 13.2%. Vanguard Group Inc. owns 994,671 of the company stock, worth $3,143,000, after buying an additional 115 649 shares. 60.71 % of the stock is owned by institutional investors and hedge fund.
Get Free Report
Immunic, Inc., a biopharmaceutical clinical-stage company, develops a portfolio of oral immunology treatments for the treatment chronic inflammatory diseases and autoimmune disorders. IMU-838 is its lead development program, and is currently in Phase 3 of clinical trials for the treatment of multiplesclerosis including relapsing MS and other chronic inflammatory, autoimmune and autoimmune disorders, as well as coronavirus.
MarketBeat.com offers a FREE daily email newsletter